FANCONI ANEMIA Clinical Trial
— RAFHASOfficial title:
A Phase I Study Evaluating The Use Of Rft5-Dga To Deplete Alloreactive Cells For Patients With Fanconi Anemia After Haploidentical Stem Cell Transplantation
Verified date | March 2014 |
Source | Baylor College of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
While stem cell transplantation has proven an effective means of treating a wide variety of
diseases involving hematopoietic stem cells and their progeny, a shortage of donors has
proved a major impediment to the widest application of the approach. Until recently, only
MHC identical donors could be used with safety. Such donors were originally siblings or
other closely related family members. Over the past decade, the growth of allogeneic donor
panels has allowed transplantation with stem cells obtained from a volunteer donor panel.
While it is now possible to obtain HLA identical unrelated donor stem cells for
approximately 75% of individuals of Northern European backgrounds, the situation for most
other ethnic groups is much less satisfactory. Even when a matched donor can be found, the
elapsed time between commencing the search and collecting the stem cells usually exceeds
three months, a delay that may doom many of the neediest patients. Hence there has been
considerable interest in making use of HLA haploidentical family donors. Most individuals
have a first-degree relative who would be suitable for such protocols. Fanconi anemia (FA)
is an autosomal recessive disorder characterized by the development of progressive aplastic
anemia usually evident by about age seven years and often associated with various diverse
congenital anomalies such as short stature, microcephaly, radial anomalies, horseshoe
kidney, and cafe au lait spots.
This study will determine the number of donor lymphocytes that can be given to recipients of
haploidentical stem cell transplants with Fanconi anemia after depletion of
recipient-reactive T lymphocytes by ex-vivo treatment with a fixed dose of RFT5-dgA
immunotoxin, and will result in a rate of Grade III/IV GVHD of < / = 25%.
Status | Terminated |
Enrollment | 1 |
Est. completion date | July 2009 |
Est. primary completion date | July 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A to 64 Years |
Eligibility |
Inclusion Criteria: - At the time of eligibility for infusion of allodepleted T -cells patients must satisfy the criteria below: - Patients with Fanconi anemia of all ages with severe aplasia (as evidenced by hypocellular bone marrow) who lack a suitable conventional related (i.e. 5/6 or 6/6 related) or 5/6 or 6/6 unrelated donor with at least 2 out of 3 of the following: a) ANC < 500/mm3, b) reticulocytes < 1% c) platelets < 50,000/mm3 - Diagnosis of Fanconi anemia confirmed by studies of peripheral blood or bone marrow sensitivity to mitomycinC or DEB prior to stem cell transplant. Have received a related haploidentical CD34-selected peripheral blood stem cell transplant with evidence of a full or partial hematopoietic donor chimerism (> 50%) in the peripheral blood. Exclusion Criteria: - Patients with a life expectancy (< 6 weeks) limited by diseases other than FA - Patients with active GVHD > / = Grade II - Patients with severe renal disease (i.e. creatinine greater than 3 X normal for age) - Patients with severe hepatic disease (direct bilirubin greater than 3ug/dl or SGPT greater than 500ug/dl) - Patients with a severe intercurrent infection - Lansky scale < 60 or Karnofsky < 60 |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Texas Children's Hospital | Houston | Texas |
United States | The Methodist Hospital | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Baylor College of Medicine | Center for Cell and Gene Therapy, Baylor College of Medicine, University of Texas, Southwestern Medical Center at Dallas |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine # of donor lymphocytes that can be given to recipients of haplo-SCT with FA after depletion of recipient-reactive T lymphocytes by ex-vivo tx with a fixed dose of RFT5-dgA immunotoxin, and will result in Grade III/IV GVHD of < / = 25%. | 1 yr | Yes | |
Secondary | To analyze immune reconstitution in these patients. | 1 yr | No | |
Secondary | To measure their overall and disease free survival, at 100 days and at 1 year after transplant. | 1 yr | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02931071 -
Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1
|
Phase 2 | |
Terminated |
NCT01319851 -
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT00084695 -
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
|
Phase 2 | |
Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Recruiting |
NCT01146210 -
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
|
N/A | |
Completed |
NCT01082133 -
Multicenter Transplant Study for Fanconi Anemia
|
Phase 2 | |
Completed |
NCT00965666 -
Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia
|
Early Phase 1 | |
Terminated |
NCT00290628 -
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
|
N/A | |
Recruiting |
NCT00027274 -
Cancer in Inherited Bone Marrow Failure Syndromes
|
||
Terminated |
NCT01001598 -
Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita
|
Phase 1/Phase 2 | |
Recruiting |
NCT03206086 -
Eltrombopag for People With Fanconi Anemia
|
Phase 2 | |
Recruiting |
NCT03579875 -
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
|
Phase 2 | |
Recruiting |
NCT05598515 -
Time-restricted Feeding to Reduce Inflammation in Fanconi Anemia
|
N/A | |
Active, not recruiting |
NCT03476330 -
Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia
|
Phase 2 | |
Terminated |
NCT05910853 -
Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia
|
||
Completed |
NCT03609840 -
Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
Completed |
NCT00479115 -
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100
|
Phase 1/Phase 2 | |
Completed |
NCT00352976 -
TBI Dose De-escalation for Fanconi Anemia
|
Phase 2/Phase 3 | |
Terminated |
NCT03600909 -
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
|
Phase 2 |